Belatacept for maintenance immunosuppression in lung transplantation

Christine Hui, Ryan Kern, David Wojciechowski, Jasleen Kukreja, Jeffrey A. Golden, Steven R. Hays, Jonathan P. Singer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Belatacept is a novel immunosuppressant that blocks a T-cell costimulation pathway and is approved for use in adult kidney transplant recipients. Its safety and efficacy have not been established after lung transplantation. We present a case of a lung transplant recipient treated with belatacept. A 56-year-old man underwent bilateral lung retransplantation for bronchiolitis obliterans syndrome (BOS). In the third year posttransplant, he developed hemolytic uremic syndrome (HUS) attributed to tacrolimus. Tacrolimus was changed to sirolimus. One month later, he presented with worsening renal function and HUS attributed to sirolimus. Plasmapheresis and steroid pulse were initiated with clinical improvement, and sirolimus was switched to belatacept. He experienced no episodes of cellular rejection but developed recurrent BOS. Complications during treatment included anemia and recurrent pneumonias. The safety and efficacy of belatacept in lung transplantation remains unclear; further studies are needed.

Original languageEnglish (US)
JournalJournal of Investigative Medicine High Impact Case Reports
Volume2
Issue number3
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Transplants
Lung Transplantation
Immunosuppression
Sirolimus
recipient
Maintenance
Transplantation (surgical)
Bronchiolitis Obliterans
Hemolytic-Uremic Syndrome
T-cells
Tacrolimus
Kidney
Safety
Lung
Plasmapheresis
Immunosuppressive Agents
Anemia
Pneumonia
Steroids
T-Lymphocytes

Keywords

  • Belatacept
  • Lung transplant
  • Novel immunosuppression
  • Outcomes

ASJC Scopus subject areas

  • Epidemiology
  • Safety, Risk, Reliability and Quality
  • Safety Research

Cite this

Belatacept for maintenance immunosuppression in lung transplantation. / Hui, Christine; Kern, Ryan; Wojciechowski, David; Kukreja, Jasleen; Golden, Jeffrey A.; Hays, Steven R.; Singer, Jonathan P.

In: Journal of Investigative Medicine High Impact Case Reports, Vol. 2, No. 3, 01.01.2014.

Research output: Contribution to journalArticle

Hui, Christine ; Kern, Ryan ; Wojciechowski, David ; Kukreja, Jasleen ; Golden, Jeffrey A. ; Hays, Steven R. ; Singer, Jonathan P. / Belatacept for maintenance immunosuppression in lung transplantation. In: Journal of Investigative Medicine High Impact Case Reports. 2014 ; Vol. 2, No. 3.
@article{9a11f9d476ac41948722ce872154ab47,
title = "Belatacept for maintenance immunosuppression in lung transplantation",
abstract = "Belatacept is a novel immunosuppressant that blocks a T-cell costimulation pathway and is approved for use in adult kidney transplant recipients. Its safety and efficacy have not been established after lung transplantation. We present a case of a lung transplant recipient treated with belatacept. A 56-year-old man underwent bilateral lung retransplantation for bronchiolitis obliterans syndrome (BOS). In the third year posttransplant, he developed hemolytic uremic syndrome (HUS) attributed to tacrolimus. Tacrolimus was changed to sirolimus. One month later, he presented with worsening renal function and HUS attributed to sirolimus. Plasmapheresis and steroid pulse were initiated with clinical improvement, and sirolimus was switched to belatacept. He experienced no episodes of cellular rejection but developed recurrent BOS. Complications during treatment included anemia and recurrent pneumonias. The safety and efficacy of belatacept in lung transplantation remains unclear; further studies are needed.",
keywords = "Belatacept, Lung transplant, Novel immunosuppression, Outcomes",
author = "Christine Hui and Ryan Kern and David Wojciechowski and Jasleen Kukreja and Golden, {Jeffrey A.} and Hays, {Steven R.} and Singer, {Jonathan P.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1177/2324709614546866",
language = "English (US)",
volume = "2",
journal = "Journal of Investigative Medicine High Impact Case Reports",
issn = "2324-7096",
publisher = "Sage Publications",
number = "3",

}

TY - JOUR

T1 - Belatacept for maintenance immunosuppression in lung transplantation

AU - Hui, Christine

AU - Kern, Ryan

AU - Wojciechowski, David

AU - Kukreja, Jasleen

AU - Golden, Jeffrey A.

AU - Hays, Steven R.

AU - Singer, Jonathan P.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Belatacept is a novel immunosuppressant that blocks a T-cell costimulation pathway and is approved for use in adult kidney transplant recipients. Its safety and efficacy have not been established after lung transplantation. We present a case of a lung transplant recipient treated with belatacept. A 56-year-old man underwent bilateral lung retransplantation for bronchiolitis obliterans syndrome (BOS). In the third year posttransplant, he developed hemolytic uremic syndrome (HUS) attributed to tacrolimus. Tacrolimus was changed to sirolimus. One month later, he presented with worsening renal function and HUS attributed to sirolimus. Plasmapheresis and steroid pulse were initiated with clinical improvement, and sirolimus was switched to belatacept. He experienced no episodes of cellular rejection but developed recurrent BOS. Complications during treatment included anemia and recurrent pneumonias. The safety and efficacy of belatacept in lung transplantation remains unclear; further studies are needed.

AB - Belatacept is a novel immunosuppressant that blocks a T-cell costimulation pathway and is approved for use in adult kidney transplant recipients. Its safety and efficacy have not been established after lung transplantation. We present a case of a lung transplant recipient treated with belatacept. A 56-year-old man underwent bilateral lung retransplantation for bronchiolitis obliterans syndrome (BOS). In the third year posttransplant, he developed hemolytic uremic syndrome (HUS) attributed to tacrolimus. Tacrolimus was changed to sirolimus. One month later, he presented with worsening renal function and HUS attributed to sirolimus. Plasmapheresis and steroid pulse were initiated with clinical improvement, and sirolimus was switched to belatacept. He experienced no episodes of cellular rejection but developed recurrent BOS. Complications during treatment included anemia and recurrent pneumonias. The safety and efficacy of belatacept in lung transplantation remains unclear; further studies are needed.

KW - Belatacept

KW - Lung transplant

KW - Novel immunosuppression

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=84977746980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977746980&partnerID=8YFLogxK

U2 - 10.1177/2324709614546866

DO - 10.1177/2324709614546866

M3 - Article

C2 - 26425619

AN - SCOPUS:84977746980

VL - 2

JO - Journal of Investigative Medicine High Impact Case Reports

JF - Journal of Investigative Medicine High Impact Case Reports

SN - 2324-7096

IS - 3

ER -